SG11202003612VA - Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same - Google Patents
Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving sameInfo
- Publication number
- SG11202003612VA SG11202003612VA SG11202003612VA SG11202003612VA SG11202003612VA SG 11202003612V A SG11202003612V A SG 11202003612VA SG 11202003612V A SG11202003612V A SG 11202003612VA SG 11202003612V A SG11202003612V A SG 11202003612VA SG 11202003612V A SG11202003612V A SG 11202003612VA
- Authority
- SG
- Singapore
- Prior art keywords
- cocrystals
- methods
- pharmaceutical compositions
- treatment involving
- involving same
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762580501P | 2017-11-02 | 2017-11-02 | |
PCT/US2018/058930 WO2019090059A1 (en) | 2017-11-02 | 2018-11-02 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003612VA true SG11202003612VA (en) | 2020-05-28 |
Family
ID=64572453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003612VA SG11202003612VA (en) | 2017-11-02 | 2018-11-02 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same |
Country Status (17)
Country | Link |
---|---|
US (3) | US11345677B2 (es) |
EP (1) | EP3704101A1 (es) |
JP (3) | JP7335877B2 (es) |
KR (1) | KR20200095480A (es) |
CN (2) | CN111527076B (es) |
AU (2) | AU2018360827B2 (es) |
BR (1) | BR112020008598A2 (es) |
CA (1) | CA3081535A1 (es) |
EA (1) | EA202091112A1 (es) |
IL (2) | IL305426B2 (es) |
MA (1) | MA50526A (es) |
MX (2) | MX2020004513A (es) |
PH (1) | PH12020550462A1 (es) |
SG (1) | SG11202003612VA (es) |
TW (2) | TWI839131B (es) |
UA (1) | UA127380C2 (es) |
WO (1) | WO2019090059A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200085832A1 (en) * | 2019-11-22 | 2020-03-19 | Agios Pharmaceuticals, Inc. | Deuterated analogs of an organic compound |
WO2022036033A2 (en) | 2020-08-12 | 2022-02-17 | Servier Pharmaceuticals, Llc | Solid state forms of an organic compound |
WO2023192565A1 (en) | 2022-03-31 | 2023-10-05 | Servier Pharmaceuticals Llc | Methods of treating enhancing brain tumors using combination therapy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013010564B1 (pt) * | 2010-11-01 | 2021-09-21 | Celgene Car Llc | Compostos heterocíclicos e composições compreendendo os mesmos |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
-
2018
- 2018-11-02 EP EP18812419.2A patent/EP3704101A1/en active Pending
- 2018-11-02 TW TW112106677A patent/TWI839131B/zh active
- 2018-11-02 UA UAA202003279A patent/UA127380C2/uk unknown
- 2018-11-02 KR KR1020207015661A patent/KR20200095480A/ko active IP Right Grant
- 2018-11-02 CA CA3081535A patent/CA3081535A1/en active Pending
- 2018-11-02 TW TW107139079A patent/TWI796377B/zh active
- 2018-11-02 IL IL305426A patent/IL305426B2/en unknown
- 2018-11-02 IL IL274123A patent/IL274123B2/en unknown
- 2018-11-02 SG SG11202003612VA patent/SG11202003612VA/en unknown
- 2018-11-02 CN CN201880079771.0A patent/CN111527076B/zh active Active
- 2018-11-02 MA MA050526A patent/MA50526A/fr unknown
- 2018-11-02 JP JP2020524501A patent/JP7335877B2/ja active Active
- 2018-11-02 EA EA202091112A patent/EA202091112A1/ru unknown
- 2018-11-02 MX MX2020004513A patent/MX2020004513A/es unknown
- 2018-11-02 WO PCT/US2018/058930 patent/WO2019090059A1/en unknown
- 2018-11-02 AU AU2018360827A patent/AU2018360827B2/en active Active
- 2018-11-02 US US16/760,520 patent/US11345677B2/en active Active
- 2018-11-02 CN CN202410230044.7A patent/CN118359585A/zh active Pending
- 2018-11-02 BR BR112020008598-7A patent/BR112020008598A2/pt unknown
-
2020
- 2020-04-22 PH PH12020550462A patent/PH12020550462A1/en unknown
- 2020-07-13 MX MX2022014792A patent/MX2022014792A/es unknown
-
2022
- 2022-04-19 US US17/723,666 patent/US11851417B2/en active Active
-
2023
- 2023-04-24 JP JP2023070786A patent/JP7499377B2/ja active Active
- 2023-11-08 US US18/504,859 patent/US20240343705A1/en active Pending
-
2024
- 2024-05-14 AU AU2024203186A patent/AU2024203186A1/en active Pending
- 2024-06-03 JP JP2024090124A patent/JP2024113028A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254525A1 (zh) | 治療組合物、組合和使用方法 | |
EP3371306B8 (en) | Materials and methods for treatment of hemoglobinopathies | |
IL259246A (en) | Preparations containing pharmaceutical substances and methods of using them | |
EP3341392A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PAIN | |
HK1259372A1 (zh) | 治療化合物、其組合物及使用方法 | |
IL269901B (en) | Pharmaceutical compounds and methods of treating cardiovascular diseases | |
PT3380525T (pt) | Formulações farmacêuticas e métodos que as utilizam | |
PL3373910T3 (pl) | Preparat echinomycyny, sposób wytwarzania i sposób stosowania | |
IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
IL274123B1 (en) | Co-crystals, their pharmaceutical preparations and treatment methods involving them | |
HK1217303A1 (zh) | 種治療白血病的藥物組合物及其製備方法 | |
IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
IL273850A (en) | Preparations and methods for the treatment of leprosy | |
EP3468540A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN | |
HK1258999A1 (zh) | 用於治療肝臟和維持肝臟健康的組合物、方法和藥物組合物 | |
EP3258908A4 (en) | Compositions and methods for treatment of skin infections | |
HK1245094A1 (zh) | 一種治療抑鬱症的藥物組合物及其製備方法 | |
EP3525787A4 (en) | TREATMENT METHODS AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512 | |
GB201511799D0 (en) | Composition and methods of treatment | |
GB201621737D0 (en) | Compositions and methods of treatment | |
HK1258765A1 (zh) | 治療性化合物、組合物和它們的使用方法 | |
GB201718483D0 (en) | Pharmaceutical composition for treatment of meopausal syndrome and preparation method thereof | |
EP3294417A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLIOMES | |
PL3270912T4 (pl) | Kompozycje farmaceutyczne zawierające kompleksy taksan-cyklodekstryna, sposób wytwarzania i sposoby zastosowania | |
IL271727A (en) | Method of treatment and their dosage forms |